Arkene Levy
YOU?
Author Swipe
View article: Supplementary Figure S4 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S4 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Supplementary Figure S4. Impact of azenosertib on hematologic populations in immune competent mouse models.
View article: Supplementary Table S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Supplementary Table S1: Treatment and response characteristics of selected CDX models tested with at least 60mg/kg azenosertib as single agent
View article: Supplementary Table S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Supplementary Table S5A Distribution of cells according to cell cycle state; Supplementary Table S5B: Distribution of cells according to mitotic and cell cycle phase
View article: Supplementary Table S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Supplementary Table S3: Study Representativeness Table
View article: Data from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Data from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Genomic instability and accumulation of DNA damage are hallmarks of tumor development and progression. To ensure the maintenance of genomic integrity, cells rely on a coordinated DNA damage response network that regulates cell-cycle progre…
View article: Supplementary Table S4 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S4 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Supplementary Table S4: ADME, physicochemical, and pharmacokinetic properties of azenosertib.
View article: Supplementary Figure S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Supplementary Figure S5. Additional optimization of azenosertib intermittent dosing schedule
View article: Supplementary Figure S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Supplementary Figure S3. Azenosertib efficacy in solid tumor xenograft models.
View article: Supplementary Table S2 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S2 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Supplementary Table S2: List of proteins and protein modifications which in vitro expression is nominally (P-value<0.05) associated with in vivo response in pan-cancer, breast or lung NSCLC models
View article: Supplementary Figure S2 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S2 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Supplementary Figure S2: Cytometric analysis of cell lines treated with azenosertib.
View article: Supplementary Table S6 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S6 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Supplementary Table S6: Distribution of cells according to γH2Ax status in both treatments conditions (A) or in azenosertib treated cells in different cell cycle phase (B) or mitotic (C) context for each cell lines.
View article: Supplementary Figure S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Supplementary Figure S1: Evaluation of azenosertib in cellular assays.
View article: Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors Open
Genomic instability and accumulation of DNA damage are hallmarks of tumor development and progression. To ensure the maintenance of genomic integrity, cells rely on a coordinated DNA damage response network that regulates cell-cycle progre…
View article: Inclusive LGBTQIA+ healthcare: An interprofessional case-based experience for cultural competency awareness
Inclusive LGBTQIA+ healthcare: An interprofessional case-based experience for cultural competency awareness Open
Introduction Lesbian, Gay, Bi-sexual, Transgender, Questioning, Intersex, and Asexual (LGBTQIA+) patients report experiences of discrimination within healthcare settings due to a lack of provider knowledge and biases of healthcare workers.…
View article: Racial Identity and Relevance in Teaching Clinical Skills and Diagnostic Medicine: A Small/Pilot Focus Session to Engage Medical Educators
Racial Identity and Relevance in Teaching Clinical Skills and Diagnostic Medicine: A Small/Pilot Focus Session to Engage Medical Educators Open
Background The relevance and importance of using racial and ethnic categories in medical education is an area requiring richer discussion and engagement among all health professions educators. Objectives There is a genuine need to identify…
View article: Fifth Annual Summer Research Summit on Health Equity Organized by the Center of Excellence in Health Equity, Training and Research, Baylor College of Medicine, Houston, Texas 77030, USA on May 17, 2022
Fifth Annual Summer Research Summit on Health Equity Organized by the Center of Excellence in Health Equity, Training and Research, Baylor College of Medicine, Houston, Texas 77030, USA on May 17, 2022 Open
The fifth annual summer research summit organized by the Center of Excellence (COE) in Health Equity, Training and Research, Baylor College of Medicine (BCM), was held on May 17, 2022. The theme of this year’s summit was ‘Academic-Communit…
View article: Role and Significance of c-KIT Receptor Tyrosine Kinase in Cancer: A Review
Role and Significance of c-KIT Receptor Tyrosine Kinase in Cancer: A Review Open
c-kit is a classical proto-oncogene that encodes a receptor tyrosine kinase (RTK) that responds to stem cell factor (SCF). C-KIT signaling is a critical regulator of cell proliferation, survival, and migration and is implicated in several …
View article: A Call to Action: Preventing Opioid and Substance Abuse in South Florida Youth
A Call to Action: Preventing Opioid and Substance Abuse in South Florida Youth Open
Description The opioid crisis poses a substantial threat to youth throughout the nation. This crisis has been exacerbated by the COVID-19 pandemic, reversing some of the positive national trends in the fight against the opioid epidemic. So…
View article: Strategies to Better Treat Glioblastoma: Antiangiogenic Agents and Endothelial Cell Targeting Agents
Strategies to Better Treat Glioblastoma: Antiangiogenic Agents and Endothelial Cell Targeting Agents Open
Glioblastoma multiforme (GBM) is the most prevalent and aggressive form of glioma, with poor prognosis and high mortality rates. As GBM is a highly vascularized cancer, antiangiogenic therapies to halt or minimize the rate of tumor growth …
View article: Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy Combination Strategies
Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy Combination Strategies Open
Platinum-resistant ovarian cancer (OC) is one of the most lethal gynecological malignancies that has shown minimal improvement in 5 year overall survival rates for the past 15 years. This chapter discusses the current targeted therapies th…
View article: Key Genes in Prostate Cancer Progression: Role of MDM2, PTEN, and TMPRSS2-ERG Fusions
Key Genes in Prostate Cancer Progression: Role of MDM2, PTEN, and TMPRSS2-ERG Fusions Open
In recent years, multiple genes or their protein products have been linked to initiation and progression of prostate cancer. Such genes include TMPRSS2, ERG, PTEN, and MDM2. This chapter discusses the pathological roles as well as the pote…
View article: A Potential Role for the Antidiabetic Drug Metformin in the Treatment of Platinum Resistant Ovarian Cancer
A Potential Role for the Antidiabetic Drug Metformin in the Treatment of Platinum Resistant Ovarian Cancer Open
Objective:The treatment of ovarian cancer is complicated by high drug-resistance often linked to over-expression of focal adhesion kinase (FAK).Additionally, cancer cells preferentially metabolize glucose and hyperglycaemia is considered a…